VitMode

Tool

Supplement comparison tool

Pick up to 4 knowledge base entries and compare their dosage, price, evidence strength and ratings side by side — you can save or share a link to your selection.

Add to comparison (2/4)

 
Tirzepatide
Minoxidil
CategoryLekiLeki
Evidence strengthStrong evidenceStrong evidence
Evidence Score5/55/5
User rating4.5 (58)4.5 (168)
Typical doseStart at 2.5 mg weekly, gradual escalation every 4 weeks to a maintenance dose of 5, 7.5, 10, 12.5, or a maximum of 15 mg weekly, depending on tolerance and treatment goalTopical form: 1 ml of 5% solution or the equivalent foam dose, applied twice daily to dry scalp (women sometimes use 5% foam once daily or a 2% solution). Oral form (LDOM, off-label): typically 0.625-5 mg/day, most often 1.25-2.5 mg, individually dosed by a physician
FormSolution for subcutaneous injection in a single-use autoinjector (Mounjaro, Zepbound)Topical solution or foam; tablets split for the oral form (compounding pharmacy preparation)
Average priceok. 1000–1600 zł za opakowanie miesięczne, zależnie od dawki i apteki35-90 zł za opakowanie formy miejscowej starczające na miesiąc stosowania (cena zależy od koncentracji, formy i producenta — generyki są tańsze niż marki oryginalne)
Monthly costok. 1000–1600 zł/miesiącok. 35-90 zł/miesiąc dla formy miejscowej; forma doustna (receptura) zwykle wychodzi wyraźnie taniej, ale wymaga recepty i wizyty lekarskiej
Time to effectsReduced appetite is sometimes noticeable within the first few weeks, but meaningful, measurable weight loss develops gradually over several months, and the full effect assessed in SURMOUNT-1 was measured after 72 weeks (about 1.5 years) of regular treatment.The temporary shedding phase can appear as early as weeks 2-8 of treatment. The first visible signs of regrowth usually appear after 3-4 months of consistent use, with a fully assessable clinical effect after 6-12 months of uninterrupted treatment. The effect requires indefinite continuation; it fades within a few months of stopping.
Who it's forPeople with type 2 diabetes with inadequate glycemic control on other oral medicationsMen with early- to moderate-stage androgenetic alopecia, especially in the crown area (less effective where follicles are already completely lost in advanced frontal balding)